Asthma caused by durvalumab after chemoradiotherapy in two patients with non‐small cell lung cancer

Asthma caused by durvalumab after chemoradiotherapy in two patients with non‐small cell lung cancer

Abstract Durvalumab, an anti‐programmed cell death‐ligand 1 (PD‐L1) antibody, is currently used in the maintenance therapy for patients with stage III non‐small cell lung cancer after platinum‐based chemoradiotherapy. A 69‐year‐old male with lung adenocarcinoma, clinical stage IIIA, was treated with...

Full description

Bibliographic Details
Main Authors: Takehiro Uemura, Kensuke Fukumitsu, Ken Maeno, Satoshi Fukuda, Tomohiro Onuki, Yoshihiro Kanemitsu, Tetsuya Oguri, Akio Niimi, Toyoaki Hida
Format: Article
Language:English
Published: Wiley 2021-09-01
Series:Respirology Case Reports
Subjects:
adverse event
asthma
durvalumab
immune checkpoint inhibitors
non‐small cell lung cancer
Online Access:https://doi.org/10.1002/rcr2.835

Internet

https://doi.org/10.1002/rcr2.835

Similar Items